|Dr. Arthur O. Tzianabos Ph.D.||CEO & Director||912.5k||N/A||1963|
|Dr. Albert Seymour Ph.D.||Pres & Chief Scientific Officer||638.7k||N/A||1968|
|Mr. W. Bradford Smith CPA, M.B.A.||CFO, Treasurer & Chief Bus. Officer||755.8k||N/A||1956|
|Dr. Saswati Chatterjee Ph.D.||Co-Founder & Member of Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Julie Jordan M.D.||Sr. VP and Head of Clinical Devel. & Operations||N/A||N/A||N/A|
|Dr. Paul Alloway J.D., Ph.D.||Chief Legal Officer & Sec.||N/A||N/A||1971|
|Ms. Theresa McNeely||Chief Communications Officer & Patient Advocate||N/A||N/A||1964|
|Ms. Melissa Gelormini||VP of HR||N/A||N/A||N/A|
|Mr. Michael Blum M.B.A.||Chief Commercial Officer||N/A||N/A||1968|
|Dr. Deborah Kinch Ph.D.||Chief Devel. Officer||N/A||N/A||N/A|
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
Homology Medicines, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 7. The pillar scores are Audit: 4; Board: 6; Shareholder Rights: 8; Compensation: 8.